Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
Business websites
JNJ.com
NewPharm.com
JnJMedTech.com
J&J MedTech
US • English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
Switzerland
English
Switzerland
Français
US
English
United Kingdom
English
Latest News
Back
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Back
Discover J&J
Back
Our Credo
Our Leadership
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Innovative Medicine
MedTech
Our societal impact
Back
Global Community Impact
Global Public Health
Global environmental sustainability
Suppliers
Back
Responsible Supply Base
Supplier Enabled Innovation
Supplier Resources
Careers
Back
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Investors
Back
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Latest News
Back
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Back
Discover J&J
Back
Our Credo
Our Leadership
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Innovative Medicine
MedTech
Our societal impact
Back
Global Community Impact
Global Public Health
Global environmental sustainability
Suppliers
Back
Responsible Supply Base
Supplier Enabled Innovation
Supplier Resources
Careers
Back
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Investors
Back
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Search Query
Submit Search
Dictate search request
Recently Viewed
Listening...
Show Search
Menu
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Dictate search request
Listening...
1,914 Results
Date
All Dates (1914)
Past 30 days (15)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1914)
Corporate (131)
ESG (1)
Financial (282)
Global Public Health (58)
Leadership (20)
Medical technologies (257)
Pharmaceuticals (859)
Research (42)
1,914 results
Filters
Date
All Dates (1914)
Past 30 days (15)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1914)
Corporate (131)
ESG (1)
Financial (282)
Global Public Health (58)
Leadership (20)
Medical technologies (257)
Pharmaceuticals (859)
Research (42)
Sort By:
Newest
Newest
Relevance
Oldest
March 7, 2024
Johnson & Johnson Completes Acquisition of Ambrx
Acquisition strengthens Johnson & Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics
Read more
March 6, 2024
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk of progression or death, compared to standard of care regimen.1
Read more
March 1, 2024
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations National Comprehensive Cancer Network ® (NCCN ®) updated its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) to recommend amivantamab-vmjw (RYBREVANT®) plus chemotherapy as a preferred first-line regimen for patients with NSCLC with EGFR exon 20 insertion mutations
Read more
February 29, 2024
Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform
Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow. Integrated with the world’s leading CARTO™ 3D Cardiac Mapping System for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AF). CE Mark follows recent approval of the VARIPULSE™ Platform in Japan.
Read more
February 27, 2024
Biosense Webster Begins Enrollment of Pivotal Trial Evaluating the Laminar Left Atrial Appendage Elimination Device
Investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation
Read more
February 26, 2024
Johnson & Johnson Announces Expansion of IMBRUVICA® (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications
IMBRUVICA® is now the only Bruton’s tyrosine kinase inhibitor (BTKi) approved with an oral suspension formulation, providing additional flexibility for patients who may have difficulty swallowing tablets or capsules
Read more
February 23, 2024
Janssen Receives Positive CHMP Opinion for CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma
Results from the Phase 3 CARTITUDE-4 study, which supported the CHMP recommendation, showed that cilta-cel has the potential to offer significant benefit to patients in earlier lines of treatment1 Most patients with multiple myeloma relapse after current standard treatments and remain in need of additional therapeutic options at earlier stages of the disease1
Read more
February 20, 2024
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Biweekly dosing with TECVAYLI®, the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility
Read more
February 14, 2024
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
Read more
February 12, 2024
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
Read more
Load More
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue